Sophie Postel‐Vinay
Inserm(FR)Inserm(FR)Université Paris-Saclay(FR)Cancer Institute (WIA)(IN)Institut Gustave Roussy(FR)London Cancer(GB)Prostate Cancer Research(GB)CRUK Lung Cancer Centre of Excellence(GB)Bicêtre Hospital(FR)University College London(GB)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, DNA Repair Mechanisms, Lung Cancer Treatments and Mutations, PARP inhibition in cancer therapy
Most-Cited Works
- → Immune-related adverse events with immune checkpoint blockade: a comprehensive review(2016)2,094 cited
- → Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1(2016)1,185 cited
- → High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial(2017)760 cited
- → Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial(2017)645 cited
- → Targeting FGFR Signaling in Cancer(2015)513 cited
- → Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study(2020)443 cited